Vital Signs - Strategic Product Life Cycle Management Partnerships as the New Means of Competitive Advantage for Medical Technology Companies

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on October 25, 2010, provides a strategic overview of key issues and trends relating to strategic product life cycle management in medical technology companies. Additionally, a company spotlight is provided for Celestica, a leading global strategic service provider to the medical devices industry. Reimbursement and regulatory news from the FDA is also provided for the week of October 4, 2010.

Table of Contents

Vital Signs - Strategic Product Life Cycle Management Partnerships as the New Means of Competitive Advantage for Medical Technology CompaniesVital Signs: 25 Oct 2010This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.